Baudax Bio Inc. (BXRX) PT Lowered to $2 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Baudax Bio Inc. (BXRX) PT Lowered to $4 at JMP Securities
May 6, 2021 3:00 AM EDTJMP Securities analyst Jason Butler lowered the price target on Baudax Bio Inc. (NASDAQ: BXRX) to $4.00 (from $5.00) while maintaining a Market Outperform rating.... More
Baudax Bio (BXRX) Misses Q1 EPS by 8c
May 5, 2021 7:27 AM EDTBaudax Bio (NASDAQ: BXRX) reported Q1 EPS of ($0.27), $0.08 worse than the analyst estimate of ($0.19).
The first quarter has been busy and fruitful at Baudax. ANJESO sustained marked progress in the areas of new account wins, increasing units sold, reorder rates, and deepening usage... More
